TCS Launches New Version Of Its Connected Clinical Trials (CCT) Platform

“Life sciences companies are embracing digital technologies to improve patient care and transform the drug development landscape. TCS’ state-of-the-art Connected Clinical Trials platform with its advanced digital technologies framework and patient-centric features will significantly improve medication adherence and patient engagement,” said Debashis Ghosh, President, Life Sciences and Healthcare, TCS.

He was speaking about the new version of the Connected Clinical Trials (CCT) platform at the recently concluded TCS ADD Vantage forum in Paris.

TCS ADD Vantage is an exclusive forum for the pharma ecosystem that brought together leaders and subject matter experts from several global pharmaceutical companies including four of the top five players, and labeling and smart medication packaging solution providers. Participants discussed industry trends and challenges, and how innovative technology solutions can enable them to become future ready.

CCT is an innovative software-as-a-service (SaaS) platform that enables life sciences companies to significantly transform patient engagement in clinical trials and improve the efficiency and accountability of the clinical supply process. CCT is part of TCS’ Advanced Drug Development (ADD) suite that offers a wide range of cloud-based clinical solutions and services, including clinical data management, metadata management, pharmacovigilance, and data analytics and insights.

The latest release of the CCT platform has the following upgraded features:

  • Intelligent Medication – Includes adherence (sensor-enabled medication packages), tracking (medication kit transactions), and labeling (electronic drug labels in user’s local language).
  • Digital Patient and Site Engagement – Includes Subject App that helps with a 360-degree interaction between patients, sites, and sponsors, and Site App and Portal, a mobile-friendly app to monitor and track all subject and medication related activities.
  • Virtual and Remote Trials – Includes consent (patient-friendly multimedia content on mobile devices, both at a site and remotely in user’s local language) and Digimarkers (end-to-end support for digital endpoints derived from smart devices, sensors, and wearables).

Says Ghosh, “Our strong contextual knowledge, deep domain expertise, and skilled talent pool help us create solutions that address industry requirements, bring benefits to the patient, and are shaping the future of clinical trials.”

For India News Follow India Pages on Facebook